Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company

Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move

Fineline Cube Jun 18, 2025

Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...

Company Deals

Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub”

Fineline Cube Jun 18, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has entered into a partnership with China’s Alibaba Health Information...

Company

Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges

Fineline Cube Jun 18, 2025

Reports indicate that China-based Legend Biotech Corporation (NASDAQ: LEGN) plans to disband its China sales...

Company Deals

Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics

Fineline Cube Jun 17, 2025

France-based Pierre Fabre Laboratories announced the acquisition of global rights to PFL-721 and PFL-241 from...

Company Deals

Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers

Fineline Cube Jun 17, 2025

China-based Hasten Biopharmaceutical Co., Ltd, backed by CBC Group, announced the completion of Market Authorization...

Company Drug

Sino Biopharmaceutical’s TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment

Fineline Cube Jun 17, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Class 1 drug TDI01 has been...

Company Deals Medical Device

3D Medicines Partners with MGI Tech for Precision Medicine Solutions in Oncology and Infectious Diseases

Fineline Cube Jun 17, 2025

China-based 3D Medicines (HKG: 1244) announced a strategic collaboration with domestic gene sequencing specialist MGI...

Company Deals

Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia

Fineline Cube Jun 17, 2025

China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical...

Company Deals

BioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline

Fineline Cube Jun 17, 2025

France-based BioMérieux is set to acquire the assets of Day Zero Diagnostics, a US-based infectious...

Company Drug

Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy

Fineline Cube Jun 17, 2025

China-based Suzhou GenAssist Therapeutic Co., Ltd. announced that its in vivo base editing therapy, GEN6050X,...

Company Deals

BioTroy Therapeutics Secures USD 28M in Series A Funding for CD3L1 Anti-Tumor Drug Development

Fineline Cube Jun 17, 2025

Shanghai-based BioTroy Therapeutics, a cancer immunotherapy developer, has reportedly secured over RMB 200 million (USD...

Company Deals

GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology

Fineline Cube Jun 17, 2025

US-based GlycoT Therapeutics LLC last week inked a license agreement with Innovent Biologics, Inc. (HKG:...

Company Deals

Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC

Fineline Cube Jun 17, 2025

China-based Shanghai Escugen has partnered with Spain-headquartered SunRock Biopharma, S.L. to co – develop SRB123,...

Company Drug

AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial

Fineline Cube Jun 17, 2025

US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...

Company Legal / IP

Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute

Fineline Cube Jun 17, 2025

China-based Harbour BioMed (HKG: 2142) announced that the China National Intellectual Property Administration (CNIPA) has...

Company Drug

Roche Advances Prasinezumab to Phase III for Early Parkinson’s Disease

Fineline Cube Jun 17, 2025

Switzerland-based Roche (SWX: ROG, OTCMKTS: RHHBY) announced its decision to advance prasinezumab, an anti-α-synuclein antibody...

Company Deals

Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors

Fineline Cube Jun 17, 2025

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming and US-headquartered NextCure, Inc. (NASDAQ:...

Company

AstraZeneca’s Oncology Executive Michael Lai to Leave Company in June

Fineline Cube Jun 17, 2025

Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and...

Company Deals

Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion

Fineline Cube Jun 17, 2025

US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...

Company Drug

Pediatrix Therapeutics Wins Macau Approval for Neffy Epinephrine Nasal Spray

Fineline Cube Jun 17, 2025

China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy...

Posts pagination

1 … 194 195 196 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.